Literature DB >> 21700944

Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.

Victor J Marder1, Ales Blinc, Theresa Gruber, Gregor Tratar, Miso Sabovic, Sidney Starkman, Reza Jahan, Gary Duckwiler, Fernando Vinuela, Satoshi Tateshima, David Liebeskind, Bruce Ovbiagele, Letisha Ali, Doojin Kim, Nestor Gonzalez, Paul M Vespa, Jeffrey L Saver.   

Abstract

BACKGROUND AND
PURPOSE: Plasmin is a direct-acting thrombolytic with a better safety profile than recombinant tissue-type plasminogen activator (rtPA) in animal models. With the application of retrieval devices for managing acute ischemic stroke, extracted thromboemboli are available for ex vivo examination. We ask whether such thrombi are amenable to plasmin thrombolysis and whether such activity is different with rtPA.
METHODS: Thromboembolic fragments (total 29) were retrieved from the intracranial carotid artery system of 15 patients with acute ischemic stroke and randomly assigned to ex vivo thrombolysis with plasmin or rtPA. After an initial 2-hour exposure, residual material was exposed to the other agent for an additional 2 hours. Thrombolysis was quantified by change in thrombus area and released d-dimer.
RESULTS: Plasmin induced significant ex vivo thrombolysis of cerebral arterial thromboemboli, decreasing area by 45.9% ± 29.4% and 69.2% ± 52.5% and inducing median D-dimer release of 108,180 μg/L (range, 16,780 to 668,050 μg/L) and 16,905 μg/L (range, 240 to 403 085 μg/L) during the first and second 2-hour incubation periods, respectively. These changes were not different from those obtained with rtPA, which decreased area by 34.7% ± 57.8% (P=0.63) and by 68.4% ± 26.9% (P=0.97) and induced median D-dimer release of 151,990 μg/L (range, 9870 to 338,350 μg/L; P=0.51) and 34,520 μg/L (range 3794 to 325,400 μg/L; P=0.19) during the first and second 2-hour incubations.
CONCLUSIONS: Retrieved human cerebral thromboemboli were amenable to ex vivo lysis by plasmin, the rate and degree of which was not different than that achieved with rtPA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700944      PMCID: PMC3217902          DOI: 10.1161/STROKEAHA.110.609198

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  22 in total

1.  D-dimer, other markers of haemostasis activation and soluble adhesion molecules in patients with different clinical probabilities of deep vein thrombosis.

Authors:  Mojca Bozic; Ales Blinc; Mojca Stegnar
Journal:  Thromb Res       Date:  2002-11-01       Impact factor: 3.944

Review 2.  Fast-acting plasmin inhibitor in human plasma.

Authors:  D Collen; B Wiman
Journal:  Blood       Date:  1978-04       Impact factor: 22.113

3.  Thrombolysis with plasmin: implications for stroke treatment.

Authors:  Victor J Marder; Reza Jahan; Theresa Gruber; Abha Goyal; Vik Arora
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

4.  Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

5.  Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.

Authors:  C A Lewandowski; M Frankel; T A Tomsick; J Broderick; J Frey; W Clark; S Starkman; J Grotta; J Spilker; J Khoury; T Brott
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

6.  Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.

Authors:  M Sabovic; H R Lijnen; D Keber; D Collen
Journal:  Thromb Haemost       Date:  1990-11-30       Impact factor: 5.249

7.  The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility.

Authors:  B J Potter van Loon; D C Rijken; E J Brommer; A P van der Maas
Journal:  Thromb Haemost       Date:  1992-01-23       Impact factor: 5.249

8.  Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.

Authors:  M Sabovic; H R Lijnen; D Keber; D Collen
Journal:  Thromb Haemost       Date:  1989-12-29       Impact factor: 5.249

9.  Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.

Authors:  Daphne Stewart; Mansze Kong; Valery Novokhatny; Gary Jesmok; Victor J Marder
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

10.  Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis.

Authors:  V Novokhatny; K Taylor; T P Zimmerman
Journal:  J Thromb Haemost       Date:  2003-05       Impact factor: 5.824

View more
  3 in total

1.  Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis.

Authors:  Kiyoshi Kikuchi; Kentaro Setoyama; Ko-Ichi Kawahara; Tomoka Nagasato; Takuto Terashi; Koki Ueda; Kazuki Nakanishi; Shotaro Otsuka; Naoki Miura; Hisayo Sameshima; Kazuya Hosokawa; Yoichiro Harada; Binita Shrestha; Mika Yamamoto; Yoko Morimoto-Yamashita; Haruna Kikuchi; Ryoji Kiyama; Chinatsu Kamikokuryo; Salunya Tancharoen; Harutoshi Sakakima; Motohiro Morioka; Eiichiro Tanaka; Takashi Ito; Ikuro Maruyama
Journal:  Oxid Med Cell Longev       Date:  2017-11-10       Impact factor: 6.543

2.  Clinical observation of mild hypothermia combined with intravenous thrombolysis in treating patients with acute cerebral infarction.

Authors:  Shaojie Zhang; Lilin Gao; Xuewen Wo; Zhonggong Wang
Journal:  Pak J Med Sci       Date:  2021 Nov-Dec       Impact factor: 1.088

3.  Uric acid enhances alteplase-mediated thrombolysis as an antioxidant.

Authors:  Kiyoshi Kikuchi; Kentaro Setoyama; Eiichiro Tanaka; Shotaro Otsuka; Takuto Terashi; Kazuki Nakanishi; Seiya Takada; Harutoshi Sakakima; Sumate Ampawong; Ko-Ichi Kawahara; Tomoka Nagasato; Kazuya Hosokawa; Yoichiro Harada; Mika Yamamoto; Chinatsu Kamikokuryo; Ryoji Kiyama; Motohiro Morioka; Takashi Ito; Ikuro Maruyama; Salunya Tancharoen
Journal:  Sci Rep       Date:  2018-10-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.